Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 14 of 14 entries
Sorted by: Best Match Show Resources per page
Kinless hubs are potential target genes in prostate cancer network.

Genomics

Mangangcha IR, Malik MZ, Kucuk O, Ali S, Singh RKB.
PMID: 32976977
Genomics. 2020 Nov;112(6):5227-5239. doi: 10.1016/j.ygeno.2020.09.033. Epub 2020 Sep 23.

Complex disease networks can be studied successfully using network theoretical approach which helps in finding key disease genes and associated disease modules. We studied prostate cancer (PCa) protein-protein interaction (PPI) network constructed from patients' gene expression datasets and found...

Cite
Mangangcha IR, Malik MZ, Kucuk O, et al. Kinless hubs are potential target genes in prostate cancer network. Genomics. 2020;112(6):5227-5239doi: 10.1016/j.ygeno.2020.09.033.
Mangangcha, I. R., Malik, M. Z., Kucuk, O., Ali, S., & Singh, R. K. B. (2020). Kinless hubs are potential target genes in prostate cancer network. Genomics, 112(6), 5227-5239. https://doi.org/10.1016/j.ygeno.2020.09.033
Mangangcha, Irengbam Rocky, et al. "Kinless hubs are potential target genes in prostate cancer network." Genomics vol. 112,6 (2020): 5227-5239. doi: https://doi.org/10.1016/j.ygeno.2020.09.033
Mangangcha IR, Malik MZ, Kucuk O, Ali S, Singh RKB. Kinless hubs are potential target genes in prostate cancer network. Genomics. 2020 Nov;112(6):5227-5239. doi: 10.1016/j.ygeno.2020.09.033. Epub 2020 Sep 23. PMID: 32976977.
Copy Download .nbib Format: NLM
M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.

Annals of medicine

JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C.
PMID: 34032524
Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396.

BACKGROUND: Prostate cancer (PCa) is poor response to the immunotherapy for its high heterogeneity of immune microenvironment. In this study, we aim to introduce a new immune subtype for PCa involving M2 tumour associated macrophages METHODS: Three hundred and...

Cite
JiaWei Z, ChunXia D, CunDong L, et al. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021;53(1):730-740doi: 10.1080/07853890.2021.1924396.
JiaWei, Z., ChunXia, D., CunDong, L., Yang, L., JianKun, Y., HaiFeng, D., Cheng, Y., ZhiPeng, H., HongYi, W., DeYing, L., ZhiJian, L., Xiao, X., QiZhao, Z., KangYi, X., WenBing, G., Ming, X., JunHao, Z., JiMing, B., ShanChao, Z., & MingKun, C. (2021). M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Annals of medicine, 53(1), 730-740. https://doi.org/10.1080/07853890.2021.1924396
JiaWei, Zhou, et al. "M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer." Annals of medicine vol. 53,1 (2021): 730-740. doi: https://doi.org/10.1080/07853890.2021.1924396
JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med. 2021 Dec;53(1):730-740. doi: 10.1080/07853890.2021.1924396. PMID: 34032524; PMCID: PMC8158194.
Copy Download .nbib Format: NLM
Showing 13 to 14 of 14 entries